Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

66.30 -1.74 (-2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Value Stocks Skating on Thin Ice
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
3 Growth Stocks in Hot Water
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
ANI Pharmaceuticals (NASDAQ:ANIP) Q1 Earnings: Leading The Generic Pharmaceuticals Pack
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
An Overview of ANI Pharmaceuticals's Earnings
Via Benzinga
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
3 Healthcare Stocks with Mounting Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
3 Cash-Producing Stocks in the Doghouse
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
ANIP Q1 CY2025 Earnings Call: Generics, Rare Disease Drive Growth; Retina Headwinds Noted
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) exceeded Wall Street’s revenue expectations in Q1 CY2025, as sales rose 43.4% year on year to $197.1 million. Its non-GAAP EPS of... 
Via StockStory
Topics World Trade
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
Via Benzinga
1 Russell 2000 Stock with Solid Fundamentals and 2 to Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Value Stocks with Mounting Challenges
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
ANI Pharma Reports Upbeat Q1 Earnings, Revises Full-Year Outlook: Retail’s Pleased
The CEO dismissed the impact of Trump tariffs, noting that the company produces a major portion of its goods in the U.S. 
Via Stocktwits
Topics Government World Trade
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth. 
Via Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) Reports Strong Q1, Full-Year Outlook Slightly Exceeds Expectations
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 43.4% year on year to $197.1 million. The... 
Via StockStory
Earnings Scheduled For May 9, 2025
Via Benzinga
Earnings To Watch: ANI Pharmaceuticals (ANIP) Reports Q1 Results Tomorrow
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be announcing earnings results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Keep Off Your Radar
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?
Even during a down period for the markets, ANI Pharmaceuticals has gone against the grain, climbing to $68.06. Its shares have yielded a 16.1% return over the last six months, beating the S&P 500 by... 
Via StockStory
Topics Stocks Supply Chain
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
3 Russell 2000 Stocks in the Doghouse
Small-cap stocks in the Russell 2000 can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Growth Stock to Target This Week and 2 to Avoid
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID... 
Via StockStory
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.